Current studentsExisting staffContact us
 

A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant

Simple item page
dc.contributor.authorDavis, I.D.
dc.contributor.authorQuirk, J.
dc.contributor.authorMorris, L.
dc.contributor.authorSeddon, L.
dc.contributor.authorTai, T.Y.
dc.contributor.authorWhitty, G.
dc.contributor.authorCavicchiolo, T.
dc.contributor.authorEbert, L.
dc.contributor.authorJackson, H.
dc.contributor.authorBrowning, J.
dc.contributor.authorMacGregor, D.
dc.contributor.authorWittke, F.
dc.contributor.authorWinkels, G.
dc.contributor.authorAlex, R.
dc.contributor.authorMiloradovic, L.
dc.contributor.authorMaraskovsky, E.
dc.contributor.authorChen, W.
dc.contributor.authorCebon, J.
dc.date.issued2017
dc.description.abstractAim: Pilot clinical trial of NY-ESO-1 (ESO) protein in ISCOMATRIX™ adjuvant pulsed onto peripheral blood dendritic cells (PBDC), to ascertain feasibility, evaluate toxicity and assess induction of ESO-specific immune responses. Patients & methods: Eligible participants had resected cancers expressing ESO or LAGE-1 and were at high risk of relapse. PBDC were produced using CliniMACS®plus, with initial depletion of CD1c+ B cells followed by positive selection of CD1c+ PBDC. Patients received three intradermal vaccinations of ESO/IMX-pulsed PBDC at 4-week intervals. Results: The process was feasible and safe. No vaccine-induced immune responses were detected. Assays of immunomodulatory cells did not correlate with outcomes. One patient had a long lasting complete remission. Conclusion: This method was feasible and safe but was minimally immunogenic.
dc.identifier.citationImmunotherapy, 2017; 9(3):249-259
dc.identifier.doi10.2217/imt-2016-0132
dc.identifier.issn1750-743X
dc.identifier.issn1750-7448
dc.identifier.orcidEbert, L. [0000-0002-8041-9666]
dc.identifier.urihttps://hdl.handle.net/11541.2/139333
dc.language.isoen
dc.publisherFuture Medicine
dc.rightsCopyright 2017 Future Medicine
dc.source.urihttps://doi.org/10.2217/imt-2016-0132
dc.subjectantigens
dc.subjectclinical trial
dc.subjectdendritic cells
dc.subjectISCOMATRIX™ adjuvant
dc.subjectNY-ESO-1
dc.subjectBlood Cells
dc.subjectT-Lymphocytes
dc.subjectCells, Cultured
dc.subjectHumans
dc.subjectCarcinoma, Basal Cell
dc.subjectSkin Neoplasms
dc.subjectNeoplasm Metastasis
dc.subjectCholesterol
dc.subjectGlycoproteins
dc.subjectSaponins
dc.subjectPhospholipids
dc.subjectMembrane Proteins
dc.subjectAntigens, CD1
dc.subjectCancer Vaccines
dc.subjectAntigens, Neoplasm
dc.subjectDrug Combinations
dc.subjectNeoplasm Staging
dc.subjectTreatment Outcome
dc.subjectImmunotherapy
dc.subjectFollow-Up Studies
dc.subjectPilot Projects
dc.subjectLymphocyte Activation
dc.subjectAntigen Presentation
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectImmunity, Humoral
dc.titleA pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant
dc.typeJournal article
pubs.publication-statusPublished
ror.mmsid9916284684401831

Files

Collections